The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV).

ABSTRACT: Cervical cancer (CC) and other malignant malignancies are acknowledged to be primarily caused by persistent human papillomavirus (HPV) infection. Historically, vaccinations against viruses that produce neutralizing antibodies unique to the virus have been an affordable way to manage viral diseases. CC risk is decreased, but not eliminated, by HPV vaccinations. Since vaccinations have been made available globally, almost 90% of HPV infections have been successfully avoided. On the lesions and diseases that are already present, however, no discernible treatment benefit has been shown. As a result, therapeutic vaccines that elicit immune responses mediated by cells are necessary for the treatment of established infections and cancers. mRNA vaccines possess remarkable potential in combating vi

SUBMITTER: Movahed F 

PROVIDER: S-EPMC11143593 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature